Replimune Total Assets from 2010 to 2026
| REPL Stock | USD 7.78 0.03 0.39% |
Total Assets | First Reported 2017-03-31 | Previous Quarter 389.4 M | Current Value 333.6 M | Quarterly Volatility 195.5 M |
Check Replimune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Replimune's main balance sheet or income statement drivers, such as Interest Income of 935.8 K, Depreciation And Amortization of 7.2 M or Interest Expense of 9.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.79. Replimune financial statements analysis is a perfect complement when working with Replimune Valuation or Volatility modules.
Replimune | Total Assets | Build AI portfolio with Replimune Stock |
Historical Total Assets data for Replimune serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Replimune Group represents a compelling investment opportunity.
Latest Replimune's Total Assets Growth Pattern
Below is the plot of the Total Assets of Replimune Group over the last few years. Total assets refers to the total amount of Replimune assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Replimune Group books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Replimune's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Replimune's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 551.33 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Replimune Total Assets Regression Statistics
| Arithmetic Mean | 254,368,256 | |
| Geometric Mean | 113,096,223 | |
| Coefficient Of Variation | 98.57 | |
| Mean Deviation | 227,103,007 | |
| Median | 154,326,000 | |
| Standard Deviation | 250,733,602 | |
| Sample Variance | 62867.3T | |
| Range | 623.8M | |
| R-Value | 0.87 | |
| Mean Square Error | 15826T | |
| R-Squared | 0.76 | |
| Slope | 43,399,869 | |
| Total Sum of Squares | 1005877.4T |
Replimune Total Assets History
Other Fundumenentals of Replimune Group
Replimune Total Assets component correlations
Click cells to compare fundamentals
About Replimune Financial Statements
Replimune investors utilize fundamental indicators, such as Total Assets, to predict how Replimune Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Assets | 634 M | 387 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Replimune Correlation against competitors. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. Anticipated expansion of Replimune directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Replimune assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Replimune's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Replimune should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Replimune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.